Market Access

  • Specialism

  • Lifecycle Stage

GNMA 10: Policy and public affairs for life science companies

GNMA 9: Supranational HTAs

GNMA 8: Market access for medtech, diagnostics and digital technologies in the UK

GNMA 7: Impact of Brexit on the regulatory approval process for medicines in the UK

GNMA 6: Impact of conditional approval and approval under exceptional circumstances on national pricing and reimbursement

GNMA 5: Learning from previous NICE consultations

GNMA 4: Cell and Gene Therapies – innovative contracting trends in Europe

GNMA 3: How can early access schemes support accelerated patient access in Europe?

GNMA 2: Top five reasons why products fail to achieve a positive NICE recommendation

GNMA 1: Improving access to orphan medicines

Sign-Up For Free

Sign-up to receive up-to-date information and advice on tax developments within your industry.

Sign-up for free